with our 2022 U.S. federal R&D credit. We intend to invest substantially all of our foreign subsidiary earnings, as well as our capital in our foreign subsidiaries, indefinitely outside of the U.S. in those jurisdictions in which we would incur significant, additional costs upon repatriation of such amounts. Deferred income tax assets and liabilities are as follows (in millions): December 31, 2022 2023 Deferred tax assets (1): Loss carryforwards U.S. - Federal/States 386 610 Loss carryforwards - Foreign 2,831 2,796 Accrued liabilities, reserves, and other expenses 3,280 3,751 Stock-based compensation 4,295 5,279 Depreciation and amortization 1,009 1,114 Operating lease liabilities